LIMN
Liminatus Pharma, Inc.Company Information
- Company Name
- Liminatus Pharma, Inc.
- CIK
- CIK0001971387
- Category
- <br>Emerging growth company
- Ticker: Exchange
- LIMN: Nasdaq, LIMNW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- LIMN
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 616,622
- Shares outstanding
- 48,398,314
- Ownership
- 1.27%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -47.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | 0 | 0 | 0 | 0 | -2 | 2 | ||||||
Assets | ||||||||||||
| Accrued Liabilities Current | - | - | - | - | - | 0 | ||||||
Assets Current | ||||||||||||
| Cash | 3 | 2 | 0 | 1 | 1 | - | ||||||
| Deferred Costs Current | - | - | 0 | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 1 | 0 | 0 | 0 | - | ||||||
| Assets Current | 3 | 3 | 1 | 1 | 2 | - | ||||||
Assets Noncurrent | ||||||||||||
| Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock | - | - | - | - | - | -0 | ||||||
| Other Receivable After Allowance For Credit Loss Noncurrent | - | - | - | 0 | 0 | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Assets | 3 | 3 | 1 | 1 | 2 | - | ||||||
Liabilities Current | ||||||||||||
| Accounts Payable And Accrued Liabilities Current | 1 | 1 | 1 | 1 | 0 | - | ||||||
| Short Term Borrowings | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Liabilities Current | 3 | 3 | 10 | 3 | 11 | - | ||||||
| Warrants And Rights Outstanding | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities | 3 | 3 | 10 | 3 | 11 | 0 | ||||||
Stockholders Equity | ||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 42 | 40 | 29 | 29 | 20 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -41 | -40 | -39 | -31 | -29 | -0 | ||||||
| Stockholders Equity | 0 | -0 | -10 | -2 | -9 | -20 | ||||||
| Liabilities And Stockholders Equity | 3 | 3 | 1 | 1 | 2 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 56 | 45 | 27 | 27 | 26 | 0 | ||||||
| Shares Outstanding | 56 | 45 | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLiminatus Pharma, Inc. (LIMN) — SEC Financial Statements & Analysis
Liminatus Pharma, Inc. (LIMN) is a biological products, (no diagnostic substances) company, incorporated in DE. Liminatus Pharma, Inc. trades on Nasdaq as: LIMN, LIMNW. Liminatus Pharma, Inc. (LIMN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Liminatus Pharma, Inc. carries a market cap of $266.19M, a P/E ratio of -21.26x, a P/B ratio of 885.50x, an enterprise value of $264.62M, and an EV/EBITDA multiple of -65.13x. On profitability, it posts a Return on Equity (ROE) of 294.43% and a Return on Assets (ROA) of -471.47%. Per share, it reports EPS of $-0.26, diluted EPS of $-0.26, free cash flow per share of $-0.08, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 1.12x, a quick ratio of 0.99x, working capital of $352.04K, a debt-to-equity ratio of 10.32x, a debt ratio of 0.91, an interest coverage ratio of -53.78x, free cash flow of $-3.99M (TTM), and net debt of $-1.57M. Figures sourced from SEC EDGAR.
- Market Cap
- $266.19M
- P/E TTM
- -21.26x
- EPS TTM
- $-0.26
- P/B TTM
- 885.50x
- ROE TTM
- 294.43%
- ROA TTM
- -471.47%
- Debt To Equity
- 10.32x
- Free Cash Flow TTM
- $-3.99M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Liminatus Pharma, Inc. in?
Liminatus Pharma, Inc. (LIMN) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does LIMN trade on?
Liminatus Pharma, Inc. (LIMN) trades on the Nasdaq.
Where is Liminatus Pharma, Inc. incorporated?
Liminatus Pharma, Inc. is incorporated in DE.
When was Liminatus Pharma, Inc. (LIMN)'s most recent SEC filing?
Liminatus Pharma, Inc. (LIMN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is LIMN's market cap?
Liminatus Pharma, Inc. (LIMN) has a market capitalization of $266.19M as of 2026-06-30.
What is LIMN's EPS (earnings per share)?
Liminatus Pharma, Inc. (LIMN)'s trailing twelve month EPS is $-0.26 as of 2026-06-30.
What is LIMN's ROE (return on equity)?
Liminatus Pharma, Inc. (LIMN)'s trailing twelve month Return on Equity (ROE) is 294.43% as of 2026-06-30.
What is LIMN's ROA (return on assets)?
Liminatus Pharma, Inc. (LIMN)'s trailing twelve month Return on Assets (ROA) is -471.47% as of 2026-06-30.
What is LIMN's EV/EBITDA?
Liminatus Pharma, Inc. (LIMN)'s trailing twelve month EV/EBITDA is -65.13x as of 2026-06-30.